



SCAENE CYBERNETICS LIMITED.

(an ISO 13485-2003 & ISO 9001-2000)

Corporate Office:

S-CARD Campus, Seegehalli Main Road, Virgonagar Post, Bangalore - 560 049.
Tel: +91 80 25614879, +91 80 25614880 Fax : + 91 80 25614878 E-mail: scalene_card@yahoo.com



ISO9001: 2000
A16265

PRESS RELEASE

Indian Therapeutic Device Receives EU Certification The Path-breaking Cytotron®: is now CE approved by UL

Bangalore, August 19: Centre for Advanced Research and Development (CARD) the research wing of Scalene Cybernetics Limited; the city-based organization engaged in research on cutting edge medical electronic, Telecom and Energy technologies announced that its path-breaking invention for non-invasive treatment of cancer and osteoarthritis – the Cytotron, has been CE certified, by Underwriters Laboratories (UL). The Cytotron has obtained the European Union (EU) Certification under Annex II, Section 3, of the Medical Devices Directive (MDD), 93/42/EEC as class IIA Medical Device.

Mr. R.A. Venkitachalam, Vice-President and Managing Director, Underwriters Laboratories (UL), Emerging Markets, the worldwide leader in product safety certification, handed over the CE certificate to Dr. Rajah Vijay Kumar, Chairman of Scalene Cybernetics, a medical engineering specialist and a scientist-inventor behind the Cytotron. Over two decades ago, Dr Kumar began his research on Rotational Field Quantum Nuclear Magnetic Resonance or RFQMR technology, on which Cytotron is based. Today, he holds worldwide patents and has received international acclaim for his work. According to Dr. Kumar, “the development of this technology started way back in 1987. The basic idea behind this technology is to alter the Tran-Membrane Potential (TMP, -potential or voltage difference between the inside and outside of the cell membrane) in human tissue to stimulate specific protein using TMP pathways resulting in tissue regeneration or degeneration as required.”

On this occasion Mr. R.A Venkitachalam, mentioned, “We at Underwriters Laboratories (UL) are happy to be associated with Scalene Cybernetics Limited and its cutting edge cancer treatment device Cytotron. We have subjected the product to various stringent tests under the CE programme, and now are proud to declare the Cytotron is CE certified by us. UL evaluates more than 19,535 types of products, components, materials and systems annually with 20 billion UL Marks appearing on 72,302 manufacturers’ products in the global marketplace each year. In addition to access, the globally recognized safety certification boosts consumer confidence in new technology.”

Dr. Kumar informed that approximately 140 terminal cancer patients had undergone treatment so far through the Cytotron during clinical trials. Of these, the one-year survival rate was 52% while 92% of the patients had improved quality of life, for whatever period they lived, as assessed by accepted quality of life assessment protocols. “The technology has a proven track record and 52 per cent of the end stage cancer patients, who were expected to live for a month or two have survived more than a year. The three primary aims we are looking with this technology are arrest cancer growth, stop its spread from organ to organ and provide better quality of life,” said Dr. Kumar.

With the Cytotron now being recognized and accepted as one of the therapeutic modality with the grant of the EU certification, there has been a widespread interest in the technology for treatment of Cancer and Osteoarthritis. The Company has received requisitions to install the Cytotron from Europe, Middle-East, Australia, Malaysia, Canada, New Zealand, South Africa and Mexico. Dr. Kumar informed that he expected over one thousand Cytotron machines to be installed around the globe by 2015, providing relief and better quality of life to patients.

On the relevance of CE certification, Venkitachalam explained, “The CE mark is the most mandatory requirement for placement in the European Economic Area (EEA). The CE certification, which is one of the

most respected marks in the world, ensures adherence to the various consumer safety, health and environmental benchmarks of the EEA countries. There are about 25 directives under the CE marking”.

Underwriters Laboratories (UL) is an independent product safety certification organization that has been writing standards for Safety, testing products and involved in conformity assessment since 1894. UL's worldwide family of companies and network of service providers includes 64 laboratory, testing and certification facilities serving customers with business operations. Currently there are 117 UL inspection centres worldwide and the company has customers from 98 countries. UL represents quality and trust to millions of customers worldwide. Being one of the world's largest Conformity Assessment Service Providers backed by more than a century of experience in product testing and inspection; UL has assessed, tested or inspected billions of products, systems and processes. Conformity assessment means accrediting features as per defined standards, regulations and other specializations.

The Cytotron, a breakthrough innovation, is different from other treatments for cancer like surgery, radiotherapy and chemotherapy for the cancer patients. Based on Rotational Field Quantum Nuclear Magnetic Resonance (RFQMR) technology, the treatment modality through Cytotron is highly advanced treatment that shows phenomenal improvement in patient's quality of life, without leaving any major side-effect, in-fact combining Cytotron with chemotherapy, substantially reduces the side effects of even powerful chemotherapeutic molecules. On the other hand Cytotron Radiosensitize the tumor for traditional Radiotherapy to work better on the tumor and reduce collateral damages as the surrounding tissue will have lower radio-sensitivity. “Conventional radiotherapy uses ionising radiation at the high frequency end of the spectrum and can cause collateral damage however, Cytotron uses a more benign, non-ionising variable proton density guided resonance approach (the cells that sing the loudest will be attacked first, these are the cancer stem cells, the next in line is poorly differentiated cells, than the moderately differentiated and finally well differentiated ones, normal cells don't sing at all so they are never attacked” and thus said to have no side effects.” said Dr. Kumar.

The Cytotron looks like a MRI scanner, with a big bore; it has a gantry carrying 864 guns or radiating antennae, each of which produces Radio frequency (RF) radiation simultaneously with high instantaneous magnetic field. These signals are delivered using a special near field antenna and parabolic reflectors to the deviantly behaving biological tissues. RFQMR is the technology and science behind the device Cytotron this will soon emerge as an important branch of science.

About Scalene Cybernetics

Scalene Cybernetics Limited is a public company incorporated under the companies Act 1956. It was established in the year 2001 as part of Organisation De Scalene with an aim to develop intelligent and unique technologies for the benefit of mankind. Organization De Scalene was established in 1993. Scalene Cybernetics Limited has its corporate office spread over 86,000 sq. feet at S-CARD Campus, on Seeghahalli Main Road, a suburb of Bangalore, India.

The Board of Directors under the Chairmanship of Dr. Rajah Vijay Kumar manages Scalene Cybernetics Limited. Being a technology-oriented company it has established a well-equipped state-of-the-art Research and Development wing named the Centre for Advanced Research and Development (CARD). Over the period it has indigenously developed many technologies in the field of Medical Engineering, Artificial Intelligence, Modeling and simulation etc., In the area of medical engineering, it has patented two important technologies the CYTOTRON® and the Haemoseis 256. Both are advanced therapeutic and diagnostic devices.

Scalene has a diverse work force consisting of Engineers, Medical Professionals, Biotechnologists, Accountants, Management professionals, administrators etc. It has it's own production facilities and conducts clinical trials of the devices it develops.

Scalene Energy Research Institute (SERI) a part of Scalene Organisation, has well advanced into Energy research and developed a new technique to produce fuel out of weeds found on the ground and water bodies that include water hyacinth, Parthenium etc., the fuel is named “Weedolin”. A Weedolin based 2.5-megawatt experimental power plant called “Project Mitochondria” is under construction at the Scalene Campus at Seeghahalli in Bangalore.

Other Members of Organization De Scalene are Scalene Engineers Private Limited, Mumbai, India; Scalene Asia Pacific Sdn. Bhd., Malaysia. Shreis Scalene Sciences LLC, MD, United States of America. Scalene Medical BV. Laiden, The Netherlands. Scalene EMEA Limited, Dubai, UAE.

About Dr. Rajah Vijay Kumar

The team that developed Cytotron® after years of research at CARD was headed by Dr Rajah Vijay Kumar DSc. Dr Kumar is a pioneering researcher and an opinion leader in the field of Biophysics and Radiobiology. Specialized in Medical Engineering, he has worked for more than fifteen years on regenerative tissue engineering and high speed biological data acquisition, modeling and simulation of the human cardiovascular system. The many patents held by him include the Realistic Geometry Cartographic Imaging (RGCI) which finds applications from medical science to tsunami detection, and the Cytotron® which is considered an important milestone in radiobiology and tissue engineering. His work on Nanotechnology has sparked off a new technique in selective tissue destruction with a "nanoblaster" that is undergoing laboratory trials. He is currently the Director and Chief Scientific Officer of the Center for Advanced Research & Development (CARD) and the Chairman of the Board of Scalene Cybernetics Limited, Bangalore, India

About UL

Underwriters Laboratories (UL) is an independent product safety certification organization that has been testing products and writing Standards for Safety for over a century. UL evaluates more than 19,000 types of products, components, materials and systems annually with 20 billion UL Marks appearing on 72,000 manufacturers' products each year. UL's worldwide family of companies and network of service providers includes 64 laboratory, testing and certification facilities serving customers in 99 countries. For more information, visit: www.ul.com.

About Mr. R.A. Venkitachalam

R.A Venkitachalam is the Vice President & Managing Director, UL Emerging Markets. Prior to joining UL India in 2003, Mr Venkitachalam was the Chief Operating Officer at BPL Mobile for Tamil Nadu, Pondicherry and Kerala. He has over 25 years of experience in the manufacturing and the service sector. His career span includes an 8 -year stint in Industrial Paints category including Asian Paints' automotive division and Shalimar Paints, before moving to Thermax Surface Coatings Limited. Mr. Venkitachalam took over as the Director and CEO of Thermax Surface Coating in 1994 before moving to Thermax Culligan in 1997. He joined BPL Mobile in October 2000. He holds a M. Tech in Industrial Management from IIT Chennai. Mr. Venkitachalam is based in Bangalore in India.

For more information, contact:

Jaya Ghosh Sharma
MelCole PR
+919999026166